Repligen Corp. Stock
Repligen Corp. Stock
The price for the Repligen Corp. stock decreased slightly today. Compared to yesterday there is a change of -€0.900 (-0.710%).
With 19 Buy predictions and not the single Sell prediction the community is currently very high on Repligen Corp..
With a target price of 149 € there is a slightly positive potential of 17.6% for Repligen Corp. compared to the current price of 126.7 €.
So far the community has only identified positive things for Repligen Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Repligen Corp. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | -0.710% | 6.112% | -1.162% | 23.584% | -9.407% | -19.241% | -35.750% |
| Opko Health Inc. | -6.710% | 10.577% | -9.449% | 3.158% | 5.485% | -29.387% | -62.747% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | 2.890% | 0.575% | 10.063% | -10.256% | -10.714% | -35.185% | -18.981% |
| China Traditional Chinese Medicine Co Ltd | 0.000% | 0.000% | 0.000% | -3.509% | 0.917% | -46.602% | -54.918% |
Comments
Repligen (RGEN) was upgraded by Citigroup Inc. to "buy".
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its "outperform" rating reaffirmed by Evercore Inc.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target lowered by HSBC Holdings plc from $170.00 to $150.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat